BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA New data on atopic dermatitis and prurigo nodularis New data ... frown lines and crow’s feet, as well as from the phase ...

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. New data on atopic dermatitis and prurigo nodularis New data on Nemluvio ... to-severe frown lines and crow’s feet, as well as from the phase IIIb ...

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. New data on atopic dermatitis and prurigo nodularis New data on Nemluvio reinforce ... treatment of moderate-to-severe frown lines and crow’s feet, as well as ...

Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

Currently, there are no approved topicals for the treatment of prurigo nodularis. According to the presenter, ruxolitinib cream 1.5% could become the first. ORLANDO — Ruxolitinib cream 1.5% ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest data drop in prurigo nodularis carries a mix of both positives and negativ | ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The UK regulator has specifically ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis (PN). The data ...

Opens in a new tab or window ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting topical ruxolitinib (Opzelura ...